ASCO: Gilead touts ADC ovarian cancer data as proof Tubulis buyout was ‘a good deal’
The German biotech shared updated data from a phase 1 study of the antibody-drug conjugate TUB-040, the star behind Gilead’s decision to buy the company for $3....
The German biotech shared updated data from a phase 1 study of the antibody-drug conjugate TUB-040, the star behind Gilead’s decision to buy the company for $3.15 billion upfront earlier this year.